(Q39839219)

15 September 2017

Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells (English)

1 reference

15 September 2017

0 references

Cyrus V Desouza

1

1 reference

PubMed ID

19520186

15 September 2017

Moira Gerety

series ordinal

2

1 reference

PubMed ID

19520186

15 September 2017

Frederick G Hamel

series ordinal

3

1 reference

15 September 2017

9 June 2009

1 reference

15 September 2017

Vascular Pharmacology

1 reference

15 September 2017

51

1 reference

15 September 2017

2-3

1 reference

15 September 2017

162-168

1 reference

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Endothelial dysfunction after drug-eluting stent was never predicted in preclinical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Signals via FGF receptor 2 regulate migration of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Genentech discloses safety concerns over Avastin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

A perspective on coronary revascularization in the PROactive 05 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Obesity, Inflammation, and Insulin Resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

Endothelial regrowth after arterial injury: from vascular repair to therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

The importance of reendothelialization after arterial injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2009.05.001

10.1016/J.VPH.2009.05.001

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

19520186